Tip:
Highlight text to annotate it
X
>>> DR. DAVID MARGILETH: One of the most common reasons that I see patients, and in fact probably
the most common, is the question of what to do with their breast cancer in the adjuvant
setting.
The adjuvant setting is defined as some additional therapy beyond their initial therapy which
is either mastectomy or lumpectomy. The questions involved revolve around ‘Do we do hormone
therapy after the surgery? Do we do chemotherapy after the surgery? Do we do both, or in some
instances, neither?’
The major types of adjuvant therapies are either hormone therapy, such as the aromatase
inhibitors, which are used in post-menopausal women, or the older drug Tamoxifen that can
be used in either pre or post-menopausal women.
The other choice is chemotherapy given in the adjuvant setting, usually intravenously,
if the circumstances of the breast cancer are such that chemotherapy is indicated. There
are a multitude of variables that go into the decision about hormone therapy, chemotherapy
or both, including such factors as estrogen receptor, progesterone receptor, HER2 new
gene analysis, size of the tumor, differentiation of the tumor, and most importantly, the status
of the lymph nodes.
Hi, I am Dr. Jay Harness and I want to share with you important information that I believe
that every newly diagnosed patient with breast cancer needs to know.
Susan Denver: I am a breast cancer survivor.
Katherine Stockton: I am a breast cancer survivor.
Coree: I am a breast cancer survivor.
Susan Denver: And I want every woman to know…
Katherine Stockton: …about personalized breast cancer treatment…
Susan Denver: …and the genomic test.
Coree: A test that helps guide a woman and her doctor…
Katherine Stockton: …to the best treatment options for her.
Susan Denver: Pass it on!